#antimicrobial-resistance

Scientific risk, weak commercial returns and unequal market access leave too few innovative antibiotics for priority resistant pathogens and limit delivery after approval.

Countries lack complete, comparable, and sustainably financed systems connecting antibiotic use, resistance, policy, and outcomes across human, animal, and environmental health.

Waste from pharmaceutical manufacturing, healthcare, households, farms and sewage systems releases antibiotics, resistant bacteria and resistance genes into environmental reservoirs.

Routine and poorly controlled antimicrobial use in livestock and aquaculture selects resistant bacteria that can spread through animals, food, workers, waste and the environment.

Many patients, especially in resource-limited settings, cannot obtain timely microbiology, susceptibility testing, or the effective antibiotics needed to treat resistant infections.

Patients and communities are exposed to resistant bacteria through preventable transmission, particularly where infection prevention, sanitation, isolation, and outbreak coordination are weak.

People worldwide face bacterial infections that no longer respond to available antibiotics, increasing treatment failure, severe illness, deaths and the risks of routine medical care.

Develop regulated phage libraries, rapid bacterial matching, stable manufacturing, and adaptive treatment protocols for infections that lack effective antibiotic options.

Prioritize antibiotics with new targets or mechanisms against critical resistant pathogens and plan registration, manufacturing, supply and stewardship across income settings before approval.

Provide grants and milestone payments for high-priority antibiotics, diagnostics and nontraditional products while attaching stewardship, access and data-sharing conditions.

Pay suppliers predictable amounts for the availability and public-health value of priority antibiotics rather than rewarding the number of doses sold.

Maintain an independent multidisciplinary body that synthesizes evidence, identifies gaps, evaluates progress and gives governments comparable guidance on effective AMR action.

Convert national AMR plans into costed, funded programmes with responsible agencies, annual milestones, outcome indicators and transparent reporting across sectors.

Connect standardized human, animal, food and environmental data on antimicrobial use and resistance so emerging threats and intervention effects can be detected and acted upon.

Keep unused medicines, contaminated manure, healthcare waste and treatment sludge out of uncontrolled drains, fields and dumps through collection, treatment and risk-based reuse rules.

Use ozonation, activated carbon, advanced oxidation, membranes, or source-specific pretreatment at high-risk facilities after effective conventional treatment, with monitoring of antibiotic residues, resistant bacteria, resistance genes, and treatment by-products.

Set enforceable antibiotic-residue limits for manufacturing wastewater and solid waste, require monitoring and audits, and make compliance part of procurement and regulatory approval.

Reduce routine antimicrobial demand by improving vaccination, hygiene, housing, stocking practices, nutrition, breeding and veterinary prevention in livestock and aquaculture.

Prohibit medically important antimicrobials for growth promotion and routine group prophylaxis while preserving supervised treatment for animals that are genuinely ill.

Coordinate registration, procurement, quality assurance, forecasting and supply so patients can obtain effective Access and Reserve antibiotics without promoting uncontrolled use.

Build affordable laboratory networks that identify bacterial pathogens and susceptibility patterns quickly enough to guide individual treatment and local resistance policies.

Provide reliable drinking water, sanitation, sewage treatment and handwashing infrastructure to interrupt infection transmission and reduce the need for antibiotics.

Increase coverage of existing vaccines (pneumococcal, Hib, influenza, rotavirus, typhoid) and develop new vaccines against high-burden bacterial pathogens to prevent resistant infections and cut antibiotic demand.

Combine hand hygiene, environmental cleaning, screening, isolation or cohorting, transfer alerts and central outbreak oversight to stop resistant bacteria spreading between patients and facilities.

Give selected low-risk patients a prescription to use only if symptoms persist or worsen, with clear safety-net instructions and rapid reassessment routes.

Integrate rapid pathogen or biomarker tests with clinical guidance, training and stewardship follow-up so results change antibiotic selection rather than merely add information.

Align treatment guidance, essential-medicine lists and purchasing with WHO Access, Watch and Reserve categories so first-line Access antibiotics are available and higher-risk products are controlled.

Create multidisciplinary stewardship teams that issue local treatment guidance, review prescribing, feed results back to clinicians and safely narrow or stop unnecessary antibiotics.

PhagoBurn was a randomized, controlled phase 1/2 trial comparing a topical anti-Pseudomonas aeruginosa phage cocktail with standard care for infected burn wounds, conducted across multiple European burn units. Manufactu…

NHS England and NICE piloted fixed annual payments for access to cefiderocol and ceftazidime-avibactam, with value assessment designed to recognize preparedness and public-health benefits rather than prescription volume…

Denmark established DANMAP in 1995 to monitor antimicrobial consumption and resistance across humans, food animals and food. Clinical laboratories, veterinary authorities and national health data contribute to annual in…

The Neugut wastewater treatment plant near Zurich was Switzerland's first full-scale municipal ozonation installation. Researchers sampled effluent at three stages — conventional treatment, ozone treatment, and biologic…

In January 2020, India published draft environmental rules proposing concentration limits for residues of 121 antibiotics in treated effluent from bulk-drug and formulation facilities — a proposal that would have create…

Beginning in 2009, the Netherlands combined national reduction targets with farm-level and veterinarian benchmarking, restrictions on critically important antibiotics, mandatory treatment plans and sector-specific anima…

China banned colistin as a growth-promoting feed additive in 2017 after plasmid-mediated mcr-1 resistance was identified in animals, food and people. Researchers compared colistin use, resistant Escherichia coli and mcr…

Denmark progressively ended antimicrobial growth promotion, beginning with specific products and followed by voluntary and regulatory withdrawal across major pig and poultry production. DANMAP (Danish Integrated Antimic…

The WASH Benefits cluster-randomized trial evaluated household water, sanitation, handwashing, and nutrition interventions among young children in rural Bangladesh. A secondary analysis examined caregiver-reported antib…

The United States introduced pneumococcal conjugate vaccination (PCV7, later expanded to PCV13) for children in 2000. Vaccination reduced invasive pneumococcal disease caused by vaccine serotypes — many of which were an…

A clonal outbreak of carbapenem-resistant Klebsiella pneumoniae spread across Israeli hospitals during 2006 and was not controlled by local measures. In 2007 the Ministry of Health mandated physical separation of carrie…

A randomized trial across 16 general practices in southwest England tested whether rapid multiplex microbiological point-of-care testing would reduce same-day antibiotic prescribing for children and adults with respirat…

Forty-eight community health centres in Vietnam were randomized to routine care or routine care with point-of-care C-reactive protein (CRP) testing for patients with non-severe acute respiratory infections. Testing was…

After macrolide resistance in group A streptococci rose in Finland, national recommendations were issued by public-health authorities and clinical professional bodies to reduce macrolide use for respiratory and skin inf…

Sweden established Strama in 1995 as a national and regional collaboration for rational antibiotic use. Regional groups combine local treatment recommendations, surveillance, professional education, prescribing feedback…